Leukemia Relapse in Donor Cells after Allogeneic Bone-Marrow Transplantation
- 19 March 1981
- journal article
- case report
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 304 (12), 712-714
- https://doi.org/10.1056/nejm198103193041206
Abstract
ABLATIVE chemotherapy with allogeneic bone-marrow transplantation has become an accepted means of therapy for acute leukemia.1 It is the only treatment capable of producing long-term unmaintained remissions in patients with acute lymphoblastic leukemia who have had relapses during the course of conventional chemotherapy, and it has been advocated for acute myeloblastic leukemia in first remission.1 An initially unforeseen and rare form of failure of such therapy has been the relapse of leukemia in donor cells.2 3 4 5 We report here our experience with a patient with acute lymphoblastic leukemia who had a relapse after therapy with high-dose cyclophosphamide, total-body irradiation, and bone-marrow . . .Keywords
This publication has 8 references indexed in Scilit:
- Bone-Marrow Ablation and Allogeneic Marrow Transplantation in Acute LeukemiaNew England Journal of Medicine, 1980
- Energy transfer-enhanced chromosome banding. An overviewCancer Genetics and Cytogenetics, 1980
- Cell surface antigens: prognostic implications in childhood acute lymphoblastic leukemiaBlood, 1980
- Cytogenetic evidence for recurrence of acute myelogenous leukemia after allogeneic bone marrow transplantation in donor hematopoietic cellsBlood, 1978
- Acute Leukemia after Alkylating-Agent Therapy of Ovarian CancerNew England Journal of Medicine, 1977
- In vivo leukemic transformation: Cytogenetic evidence of in vivo leukemic transformation of engrafted marrow cellsAmerican Journal of Hematology, 1977
- LEUKÆMIC TRANSFORMATION OF ENGRAFTED HUMAN MARROW CELLS IN VIVOThe Lancet, 1972
- LEUKÆMIC TRANSFORMATION OF ENGRAFTED HUMAN MARROW CELLS IN VIVOThe Lancet, 1971